Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Lineage Cell Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +3 vs. Q4 2023
- Shares held
- 93.4M
- +17.7M (+23.4%) vs. Q4 2023
- Total value
- $138.3M
- +$55.7M (+67.6%) vs. Q4 2023
- New holders
- 15
- 29 more added
- Sold out
- 12
- 32 more reduced
2 institutions that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q4 2023.